Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a co‑factor for DNA synthesis. By limiting DNA and RNA production, it suppresses rapidly dividing cells, including immune cells that drive inflammation and malignant cells that proliferate uncontrollably.

The dose of Methofill is individualized by the prescribing healthcare professional based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No standard dose is provided here; the prescriber will set the appropriate regimen.

Methofill is classified as pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended while breastfeeding, as methotrexate can be excreted in breast milk and may harm the infant.

To order Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with biologic DMARDs, Methofill (methotrexate) is an oral, small‑molecule agent that is generally less expensive and has a well‑established efficacy profile for rheumatoid arthritis and psoriasis. However, biologics may be preferred in patients who do not respond adequately to methotrexate or who require targeted cytokine inhibition.

Methofill should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink, and keep out of reach of children.

Methofill is supplied as an oral tablet and is taken by mouth with or without food, as directed by the prescriber. The tablet should be swallowed whole with a full glass of water; it is not intended for crushing, chewing, or sublingual administration.

The most serious risks include bone marrow suppression leading to severe anemia or infection, significant liver toxicity that can progress to fibrosis or cirrhosis, and pulmonary complications such as interstitial pneumonitis. Patients should be monitored regularly for blood counts, liver enzymes and respiratory symptoms.

Methofill should not be used by individuals who are pregnant, planning pregnancy, or breastfeeding. It is also contraindicated in patients with severe renal impairment, active liver disease, uncontrolled infections, or known hypersensitivity to methotrexate or any of the tablet excipients.